INCA has collaborated with SPARC-Europe on release of five neuroendocrine cancer patients testimonials on experience with radioligand therapy (RLT). The videos released in December 2022 feature patient stories from Italy, Bulgaria, France, Germany and Sweden.
Throughout their stories, patients outline their diagnoses and treatment pathway, their experience with radioligand therapy (RLT) and the future they foresee for the treatment and neuroendocrine neoplasms (NEN) patients, wishing to shed light to policymakers and stakeholders on this therapy known for improving patients’ quality of life.
Neuroendocrine neoplasms (NENs) and metastatic castration-resistant prostate cancer (mCRPC) are currently being treated with radioligand therapies (RLTs), a novel method of cancer treatment. One of SPARC-Europe‘s objectives is to keep promoting the advantages of this treatment by widely disseminating stories about patients’ experiences, as patient education, awareness, and understanding of the treatment all remain barriers to RLT acceptance.
In the first of the five stories, Barbara from Italy discusses the progression of her illness, the importance of making this therapy available throughout Italy, and her suggestion to shorten waiting times.
Watch the video